Shan Riku Sakakibara Sells 8,000 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $110.00, for a total value of $880,000.00. Following the transaction, the insider directly owned 208,000 shares in the company, valued at $22,880,000. The trade was a 3.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The stock was sold at an average price of $98.22, for a total value of $785,760.00.

Billiontoone Trading Up 5.3%

NASDAQ:BLLN opened at $118.17 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58. Billiontoone, Inc. has a fifty-two week low of $61.96 and a fifty-two week high of $138.70. The stock’s 50-day moving average is $92.57 and its two-hundred day moving average is $87.32. The stock has a market cap of $5.43 billion and a PE ratio of 214.85.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. Billiontoone’s revenue for the quarter was up 83.8% compared to the same quarter last year. During the same period last year, the company earned ($0.39) earnings per share. As a group, equities research analysts forecast that Billiontoone, Inc. will post 0.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BLLN. JPMorgan Chase & Co. lifted their target price on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. BTIG Research dropped their price target on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday. Finally, Guggenheim boosted their target price on Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $125.29.

Hedge Funds Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLLN. Rossby Financial LCC bought a new stake in Billiontoone in the fourth quarter worth approximately $25,000. Wells Fargo & Company MN bought a new position in shares of Billiontoone during the 4th quarter valued at $76,000. Smartleaf Asset Management LLC bought a new position in shares of Billiontoone during the 4th quarter valued at $80,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Billiontoone in the 4th quarter valued at $82,000. Finally, Renaissance Capital LLC acquired a new stake in shares of Billiontoone in the 4th quarter valued at $201,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.